Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01947023|
Recruitment Status : Active, not recruiting
First Posted : September 20, 2013
Last Update Posted : May 2, 2022
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Thyroid Gland Carcinoma Unresectable Thyroid Gland Carcinoma||Drug: Dabrafenib Drug: Dabrafenib Mesylate Drug: Lapatinib Drug: Lapatinib Ditosylate||Phase 1|
I. To determine the maximum tolerated dose of lapatinib that can be used in combination of dabrafenib.
I. To observe and record anti-tumor activity. II. Evaluate potential mechanisms of primary resistance of v-raf murine sarcoma viral oncogene homolog B (BRAF) mutant thyroid cancer to dabrafenib by performing pathway profiling of tumor biopsies before and while on therapy.
III. Obtain preliminary data on the activity of the combination of lapatinib and dabrafenib in BRAF mutant thyroid cancer through imaging.
OUTLINE: This is a dose-escalation study of lapatinib.
Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 and lapatinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib.
After completion of study treatment, patients are followed up for 4 weeks and then annually thereafter.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer|
|Actual Study Start Date :||August 29, 2013|
|Estimated Primary Completion Date :||July 1, 2022|
|Estimated Study Completion Date :||July 1, 2022|
Experimental: Treatment (lapatinib, dabrafenib)
Patients receive dabrafenib* PO BID on days 1-28 and lapatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib.
Drug: Dabrafenib Mesylate
Drug: Lapatinib Ditosylate
Other Name: Tykerb
- Maximum tolerated dose (MTD) of lapatinib, in combination with the established dose of dabrafenib [ Time Frame: First 42 days of treatment ]Will be defined as the highest dose at which not more than 1/6 of the patients experience dose limiting toxicity MTD is defined as the highest dose at which not more than 1/6 of the patients experience dose limiting toxicity.
- Mean percent change in the post-treatment tissues relative to pre-treatment tissues for the phosphorylated protein targets examined [ Time Frame: Baseline to day 7 of cycle 1 ]Tissues such as phosphorylated mitogen-activated protein kinase 1 (ERK), human epidermal growth factor receptor (HER) 2, HER3, epidermal growth factor receptor (EGFR), platelet derived growth factor (PDGF), or protein kinase B (AKT) will be examined. Mean percent change will be calculated and compared.
- Mean percentage change in transcript levels in the post-treatment tissues relative to pre-treatment tissues for several genes analyzed by reverse-transcriptase-polymerase chain reaction [ Time Frame: Baseline to day 7 of cycle 1 ]Genes including sodium/iodide symporter (NIS), dual-specificity phosphatase 5 (DUSP5), and plasminogen activator (PLAT) will be examined. Mean percentage change is calculated and compared with respect to each genotype.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01947023
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Eric J Sherman||Memorial Sloan Kettering Cancer Center|